Multiple Myeloma Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
Market Overview:
The global multiple myeloma drugs market size reached US$ 21.0 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 29.6 Billion by 2028, exhibiting a growth rate (CAGR) of 6.3% during 2023-2028.
Multiple myeloma, or Kahler's disease, refers to a form of blood cancer that primarily affects the plasma cells. Some of the most common types of multiple myeloma drugs include chemotherapeutic agents, corticosteroids and immunomodulatory agents. These pharmaceutical drugs aid in promoting bone healing, prevent hypercalcemia, bone fracture, spinal cord compression and anemia, while minimizing the need for chemotherapy. The chemotherapeutic agents include various anthracycline antibiotics and alkylating agents, such as melphalan, doxorubicin, vincristine and liposomal doxorubicin. The targeted therapy drugs include proteasome inhibitor, such as bortezomib, and various other compounds, including dexamethasone, prednisone and thalidomide.
Significant developments in the healthcare sector, along with the increasing prevalence of hematological cancer, is one of the key factors driving the growth of the market. Multiple myeloma is usually caused by specific genetic abnormalities, and the treatment of this disease involves drugs that modulate the immune system and aid in enhancing the efficiency of chemotherapies, radiation therapies, stem cell transplants and platelet transfusion. Furthermore, rising consumer awareness regarding the benefits of biologic therapy drugs, which utilize the body’s immune system to identify and attack the myeloma cells, is also providing a boost to the market growth. Additionally, various technological advancements, such as the development of microRNA therapeutics and nanomedicines for the treatment of multiple myeloma, is acting as another growth-inducing factor. These medicines are used to facilitate the delivery of macromolecular agents into the bone marrow and catalyze antitumor responses. Other factors, including the rising healthcare expenditures and extensive research and development (R&D) activities in the field of medical sciences, are projected to drive the market further.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global multiple myeloma drugs market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on therapy, drug type, end-user and distribution channel.
Breakup by Therapy:
Targeted Therapy
Biologic Therapy
Chemotherapy
Others
Breakup by Drug Type:
Immunomodulatory Drugs
Proteasome Inhibitors
Histone Deacetylase Inhibitors
Monoclonal Antibody Drugs
Steroids
Others
Breakup by End-User:
Men
Women
Breakup by Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
Breakup by Region:
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being Amgen Inc., Bristol Myers Squibb, Daiichi Sankyo Co., Ltd., Sanofi-Aventis Groupe (Genzyme Corporation), Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis International AG, Pfizer Inc., PHARMA MAR, S.A., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., etc.
Key Questions Answered in This Report:
How has the global multiple myeloma drugs market performed so far and how will it perform in the coming years?
What are the key regional markets?
What has been the impact of COVID-19 on the global multiple myeloma drugs market?
What is the breakup of the market based on the therapy?
What is the breakup of the market based on the drug type?
What is the breakup of the market based on the end-user?
What is the breakup of the market based on the distribution channel?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global multiple myeloma drugs market and who are the key players?
What is the degree of competition in the industry?
The global multiple myeloma drugs market size reached US$ 21.0 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 29.6 Billion by 2028, exhibiting a growth rate (CAGR) of 6.3% during 2023-2028.
Multiple myeloma, or Kahler's disease, refers to a form of blood cancer that primarily affects the plasma cells. Some of the most common types of multiple myeloma drugs include chemotherapeutic agents, corticosteroids and immunomodulatory agents. These pharmaceutical drugs aid in promoting bone healing, prevent hypercalcemia, bone fracture, spinal cord compression and anemia, while minimizing the need for chemotherapy. The chemotherapeutic agents include various anthracycline antibiotics and alkylating agents, such as melphalan, doxorubicin, vincristine and liposomal doxorubicin. The targeted therapy drugs include proteasome inhibitor, such as bortezomib, and various other compounds, including dexamethasone, prednisone and thalidomide.
Significant developments in the healthcare sector, along with the increasing prevalence of hematological cancer, is one of the key factors driving the growth of the market. Multiple myeloma is usually caused by specific genetic abnormalities, and the treatment of this disease involves drugs that modulate the immune system and aid in enhancing the efficiency of chemotherapies, radiation therapies, stem cell transplants and platelet transfusion. Furthermore, rising consumer awareness regarding the benefits of biologic therapy drugs, which utilize the body’s immune system to identify and attack the myeloma cells, is also providing a boost to the market growth. Additionally, various technological advancements, such as the development of microRNA therapeutics and nanomedicines for the treatment of multiple myeloma, is acting as another growth-inducing factor. These medicines are used to facilitate the delivery of macromolecular agents into the bone marrow and catalyze antitumor responses. Other factors, including the rising healthcare expenditures and extensive research and development (R&D) activities in the field of medical sciences, are projected to drive the market further.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global multiple myeloma drugs market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on therapy, drug type, end-user and distribution channel.
Breakup by Therapy:
Targeted Therapy
Biologic Therapy
Chemotherapy
Others
Breakup by Drug Type:
Immunomodulatory Drugs
Proteasome Inhibitors
Histone Deacetylase Inhibitors
Monoclonal Antibody Drugs
Steroids
Others
Breakup by End-User:
Men
Women
Breakup by Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
Breakup by Region:
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being Amgen Inc., Bristol Myers Squibb, Daiichi Sankyo Co., Ltd., Sanofi-Aventis Groupe (Genzyme Corporation), Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis International AG, Pfizer Inc., PHARMA MAR, S.A., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., etc.
Key Questions Answered in This Report:
How has the global multiple myeloma drugs market performed so far and how will it perform in the coming years?
What are the key regional markets?
What has been the impact of COVID-19 on the global multiple myeloma drugs market?
What is the breakup of the market based on the therapy?
What is the breakup of the market based on the drug type?
What is the breakup of the market based on the end-user?
What is the breakup of the market based on the distribution channel?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global multiple myeloma drugs market and who are the key players?
What is the degree of competition in the industry?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 INTRODUCTION
4.1 Overview
4.2 Key Industry Trends
5 PIPELINE ASSESMENT/CLINICAL TRIAL PRODUCTS/CLINICAL DEVELOPMENTS
5.1 PegIntron (Pegylated interferon alfa-2b)
5.2 Pomalidomide
5.3 Tanespimycin (KOS-953)
5.4 MLN 9708
5.5 SRT-501-
5.6 BHQ880
5.7 Panobinostat
5.8 ZIO-101
5.9 VEGF-Trap(Aflibercept)
5.10 Denosumab
5.11 Perifosine
5.12 Actimid (CC-5013)
5.13 Romidepsin
5.14 Plitidepsin (Aplidin)
5.15 Temsirolimus (Torisel)
5.16 Sorafenib
5.17 Bevacizumab
6 GLOBAL MULTIPLE MYELOMA DRUGS MARKET
6.1 Market Overview
6.2 Market Performance
6.3 Impact of COVID-19
6.4 Market Forecast
7 MARKET BREAKUP BY THERAPY
7.1 Targeted Therapy
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Biologic Therapy
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Chemotherapy
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Others
7.4.1 Market Trends
7.4.2 Market Forecast
8 MARKET BREAKUP BY DRUG TYPE
8.1 Immunomodulatory Drugs
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Proteasome Inhibitors
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Histone Deacetylase Inhibitors
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Monoclonal Antibody Drugs
8.4.1 Market Trends
8.4.2 Market Forecast
8.5 Steroids
8.5.1 Market Trends
8.5.2 Market Forecast
8.6 Others
8.6.1 Market Trends
8.6.2 Market Forecast
9 MARKET BREAKUP BY END-USER
9.1 Men
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 Women
9.2.1 Market Trends
9.2.2 Market Forecast
10 MARKET BREAKUP BY DISTRIBUTION CHANNEL
10.1 Hospital Pharmacies
10.1.1 Market Trends
10.1.2 Market Forecast
10.2 Retail Pharmacies
10.2.1 Market Trends
10.2.2 Market Forecast
10.3 Online Pharmacies
10.3.1 Market Trends
10.3.2 Market Forecast
10.4 Others
10.4.1 Market Trends
10.4.2 Market Forecast
11 MARKET BREAKUP BY REGION
11.1 North America
11.1.1 United States
11.1.1.1 Market Trends
11.1.1.2 Market Forecast
11.1.2 Canada
11.1.2.1 Market Trends
11.1.2.2 Market Forecast
11.2 Asia Pacific
11.2.1 China
11.2.1.1 Market Trends
11.2.1.2 Market Forecast
11.2.2 Japan
11.2.2.1 Market Trends
11.2.2.2 Market Forecast
11.2.3 India
11.2.3.1 Market Trends
11.2.3.2 Market Forecast
11.2.4 South Korea
11.2.4.1 Market Trends
11.2.4.2 Market Forecast
11.2.5 Australia
11.2.5.1 Market Trends
11.2.5.2 Market Forecast
11.2.6 Indonesia
11.2.6.1 Market Trends
11.2.6.2 Market Forecast
11.2.7 Others
11.2.7.1 Market Trends
11.2.7.2 Market Forecast
11.3 Europe
11.3.1 Germany
11.3.1.1 Market Trends
11.3.1.2 Market Forecast
11.3.2 France
11.3.2.1 Market Trends
11.3.2.2 Market Forecast
11.3.3 United Kingdom
11.3.3.1 Market Trends
11.3.3.2 Market Forecast
11.3.4 Italy
11.3.4.1 Market Trends
11.3.4.2 Market Forecast
11.3.5 Spain
11.3.5.1 Market Trends
11.3.5.2 Market Forecast
11.3.6 Russia
11.3.6.1 Market Trends
11.3.6.2 Market Forecast
11.3.7 Others
11.3.7.1 Market Trends
11.3.7.2 Market Forecast
11.4 Latin America
11.4.1 Brazil
11.4.1.1 Market Trends
11.4.1.2 Market Forecast
11.4.2 Mexico
11.4.2.1 Market Trends
11.4.2.2 Market Forecast
11.4.3 Others
11.4.3.1 Market Trends
11.4.3.2 Market Forecast
11.5 Middle East and Africa
11.5.1 Market Trends
11.5.2 Market Breakup by Country
11.5.3 Market Forecast
12 SWOT ANALYSIS
12.1 Overview
12.2 Strengths
12.3 Weaknesses
12.4 Opportunities
12.5 Threats
13 VALUE CHAIN ANALYSIS
14 PORTERS FIVE FORCES ANALYSIS
14.1 Overview
14.2 Bargaining Power of Buyers
14.3 Bargaining Power of Suppliers
14.4 Degree of Competition
14.5 Threat of New Entrants
14.6 Threat of Substitutes
15 PRICE INDICATORS
16 COMPETITIVE LANDSCAPE
16.1 Market Structure
16.2 Key Players
16.3 Profiles of Key Players
16.3.1 Amgen Inc.
16.3.1.1 Company Overview
16.3.1.2 Product Portfolio
16.3.1.3 Financials
16.3.1.4 SWOT Analysis
16.3.2 Bristol Myers Squibb
16.3.2.1 Company Overview
16.3.2.2 Product Portfolio
16.3.2.3 Financials
16.3.2.4 SWOT Analysis
16.3.3 Daiichi Sankyo Co.
16.3.3.1 Company Overview
16.3.3.2 Product Portfolio
16.3.3.3 Financials
16.3.3.4 SWOT Analysis
16.3.4 Sanofi-Aventis Groupe (Genzyme Corporation)
16.3.4.1 Company Overview
16.3.4.2 Product Portfolio
16.3.4.3 SWOT Analysis
16.3.5 Johnson & Johnson Services, Inc.
16.3.5.1 Company Overview
16.3.5.2 Product Portfolio
16.3.5.3 Financials
16.3.5.4 SWOT Analysis
16.3.6 Merck & Co., Inc.
16.3.6.1 Company Overview
16.3.6.2 Product Portfolio
16.3.6.3 Financials
16.3.6.4 SWOT Analysis
16.3.7 Novartis International AG
16.3.7.1 Company Overview
16.3.7.2 Product Portfolio
16.3.7.3 Financials
16.3.7.4 SWOT Analysis
16.3.8 Pfizer Inc.
16.3.8.1 Company Overview
16.3.8.2 Product Portfolio
16.3.8.3 Financials
16.3.8.4 SWOT Analysis
16.3.9 PHARMA MAR, S.A.
16.3.9.1 Company Overview
16.3.9.2 Product Portfolio
16.3.9.3 Financials
16.3.10 Takeda Pharmaceutical Company Limited.
16.3.10.1 Company Overview
16.3.10.2 Product Portfolio
16.3.10.3 Financials
16.3.10.4 SWOT Analysis
16.3.11 Teva Pharmaceutical Industries Ltd.
16.3.11.1 Company Overview
16.3.11.2 Product Portfolio
16.3.11.3 Financials
16.3.11.4 SWOT Analysis
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 INTRODUCTION
4.1 Overview
4.2 Key Industry Trends
5 PIPELINE ASSESMENT/CLINICAL TRIAL PRODUCTS/CLINICAL DEVELOPMENTS
5.1 PegIntron (Pegylated interferon alfa-2b)
5.2 Pomalidomide
5.3 Tanespimycin (KOS-953)
5.4 MLN 9708
5.5 SRT-501-
5.6 BHQ880
5.7 Panobinostat
5.8 ZIO-101
5.9 VEGF-Trap(Aflibercept)
5.10 Denosumab
5.11 Perifosine
5.12 Actimid (CC-5013)
5.13 Romidepsin
5.14 Plitidepsin (Aplidin)
5.15 Temsirolimus (Torisel)
5.16 Sorafenib
5.17 Bevacizumab
6 GLOBAL MULTIPLE MYELOMA DRUGS MARKET
6.1 Market Overview
6.2 Market Performance
6.3 Impact of COVID-19
6.4 Market Forecast
7 MARKET BREAKUP BY THERAPY
7.1 Targeted Therapy
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Biologic Therapy
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Chemotherapy
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Others
7.4.1 Market Trends
7.4.2 Market Forecast
8 MARKET BREAKUP BY DRUG TYPE
8.1 Immunomodulatory Drugs
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Proteasome Inhibitors
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Histone Deacetylase Inhibitors
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Monoclonal Antibody Drugs
8.4.1 Market Trends
8.4.2 Market Forecast
8.5 Steroids
8.5.1 Market Trends
8.5.2 Market Forecast
8.6 Others
8.6.1 Market Trends
8.6.2 Market Forecast
9 MARKET BREAKUP BY END-USER
9.1 Men
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 Women
9.2.1 Market Trends
9.2.2 Market Forecast
10 MARKET BREAKUP BY DISTRIBUTION CHANNEL
10.1 Hospital Pharmacies
10.1.1 Market Trends
10.1.2 Market Forecast
10.2 Retail Pharmacies
10.2.1 Market Trends
10.2.2 Market Forecast
10.3 Online Pharmacies
10.3.1 Market Trends
10.3.2 Market Forecast
10.4 Others
10.4.1 Market Trends
10.4.2 Market Forecast
11 MARKET BREAKUP BY REGION
11.1 North America
11.1.1 United States
11.1.1.1 Market Trends
11.1.1.2 Market Forecast
11.1.2 Canada
11.1.2.1 Market Trends
11.1.2.2 Market Forecast
11.2 Asia Pacific
11.2.1 China
11.2.1.1 Market Trends
11.2.1.2 Market Forecast
11.2.2 Japan
11.2.2.1 Market Trends
11.2.2.2 Market Forecast
11.2.3 India
11.2.3.1 Market Trends
11.2.3.2 Market Forecast
11.2.4 South Korea
11.2.4.1 Market Trends
11.2.4.2 Market Forecast
11.2.5 Australia
11.2.5.1 Market Trends
11.2.5.2 Market Forecast
11.2.6 Indonesia
11.2.6.1 Market Trends
11.2.6.2 Market Forecast
11.2.7 Others
11.2.7.1 Market Trends
11.2.7.2 Market Forecast
11.3 Europe
11.3.1 Germany
11.3.1.1 Market Trends
11.3.1.2 Market Forecast
11.3.2 France
11.3.2.1 Market Trends
11.3.2.2 Market Forecast
11.3.3 United Kingdom
11.3.3.1 Market Trends
11.3.3.2 Market Forecast
11.3.4 Italy
11.3.4.1 Market Trends
11.3.4.2 Market Forecast
11.3.5 Spain
11.3.5.1 Market Trends
11.3.5.2 Market Forecast
11.3.6 Russia
11.3.6.1 Market Trends
11.3.6.2 Market Forecast
11.3.7 Others
11.3.7.1 Market Trends
11.3.7.2 Market Forecast
11.4 Latin America
11.4.1 Brazil
11.4.1.1 Market Trends
11.4.1.2 Market Forecast
11.4.2 Mexico
11.4.2.1 Market Trends
11.4.2.2 Market Forecast
11.4.3 Others
11.4.3.1 Market Trends
11.4.3.2 Market Forecast
11.5 Middle East and Africa
11.5.1 Market Trends
11.5.2 Market Breakup by Country
11.5.3 Market Forecast
12 SWOT ANALYSIS
12.1 Overview
12.2 Strengths
12.3 Weaknesses
12.4 Opportunities
12.5 Threats
13 VALUE CHAIN ANALYSIS
14 PORTERS FIVE FORCES ANALYSIS
14.1 Overview
14.2 Bargaining Power of Buyers
14.3 Bargaining Power of Suppliers
14.4 Degree of Competition
14.5 Threat of New Entrants
14.6 Threat of Substitutes
15 PRICE INDICATORS
16 COMPETITIVE LANDSCAPE
16.1 Market Structure
16.2 Key Players
16.3 Profiles of Key Players
16.3.1 Amgen Inc.
16.3.1.1 Company Overview
16.3.1.2 Product Portfolio
16.3.1.3 Financials
16.3.1.4 SWOT Analysis
16.3.2 Bristol Myers Squibb
16.3.2.1 Company Overview
16.3.2.2 Product Portfolio
16.3.2.3 Financials
16.3.2.4 SWOT Analysis
16.3.3 Daiichi Sankyo Co.
16.3.3.1 Company Overview
16.3.3.2 Product Portfolio
16.3.3.3 Financials
16.3.3.4 SWOT Analysis
16.3.4 Sanofi-Aventis Groupe (Genzyme Corporation)
16.3.4.1 Company Overview
16.3.4.2 Product Portfolio
16.3.4.3 SWOT Analysis
16.3.5 Johnson & Johnson Services, Inc.
16.3.5.1 Company Overview
16.3.5.2 Product Portfolio
16.3.5.3 Financials
16.3.5.4 SWOT Analysis
16.3.6 Merck & Co., Inc.
16.3.6.1 Company Overview
16.3.6.2 Product Portfolio
16.3.6.3 Financials
16.3.6.4 SWOT Analysis
16.3.7 Novartis International AG
16.3.7.1 Company Overview
16.3.7.2 Product Portfolio
16.3.7.3 Financials
16.3.7.4 SWOT Analysis
16.3.8 Pfizer Inc.
16.3.8.1 Company Overview
16.3.8.2 Product Portfolio
16.3.8.3 Financials
16.3.8.4 SWOT Analysis
16.3.9 PHARMA MAR, S.A.
16.3.9.1 Company Overview
16.3.9.2 Product Portfolio
16.3.9.3 Financials
16.3.10 Takeda Pharmaceutical Company Limited.
16.3.10.1 Company Overview
16.3.10.2 Product Portfolio
16.3.10.3 Financials
16.3.10.4 SWOT Analysis
16.3.11 Teva Pharmaceutical Industries Ltd.
16.3.11.1 Company Overview
16.3.11.2 Product Portfolio
16.3.11.3 Financials
16.3.11.4 SWOT Analysis
LIST OF TABLES
Table 1: Global: Multiple Myeloma Drugs Market: Key Industry Highlights, 2022 and 2028
Table 2: Global: Multiple Myeloma Drugs Market Forecast: Breakup by Therapy (in Million US$), 2023-2028
Table 3: Global: Multiple Myeloma Drugs Market Forecast: Breakup by Drug Type (in Million US$), 2023-2028
Table 4: Global: Multiple Myeloma Drugs Market Forecast: Breakup by End-User (in Million US$), 2023-2028
Table 5: Global: Multiple Myeloma Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2023-2028
Table 6: Global: Multiple Myeloma Drugs Market Forecast: Breakup by Region (in Million US$), 2023-2028
Table 7: Global: Multiple Myeloma Drugs Market Structure
Table 8: Global: Multiple Myeloma Drugs Market: Key Players
Table 1: Global: Multiple Myeloma Drugs Market: Key Industry Highlights, 2022 and 2028
Table 2: Global: Multiple Myeloma Drugs Market Forecast: Breakup by Therapy (in Million US$), 2023-2028
Table 3: Global: Multiple Myeloma Drugs Market Forecast: Breakup by Drug Type (in Million US$), 2023-2028
Table 4: Global: Multiple Myeloma Drugs Market Forecast: Breakup by End-User (in Million US$), 2023-2028
Table 5: Global: Multiple Myeloma Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2023-2028
Table 6: Global: Multiple Myeloma Drugs Market Forecast: Breakup by Region (in Million US$), 2023-2028
Table 7: Global: Multiple Myeloma Drugs Market Structure
Table 8: Global: Multiple Myeloma Drugs Market: Key Players
LIST OF FIGURES
Figure 1: Global: Multiple Myeloma Drugs Market: Major Drivers and Challenges
Figure 2: Global: Multiple Myeloma Drugs Market: Sales Value (in Billion US$), 2017-2022
Figure 3: Global: Multiple Myeloma Drugs Market: Breakup by Therapy (in %), 2022
Figure 4: Global: Multiple Myeloma Drugs Market: Breakup by Drug Type (in %), 2022
Figure 5: Global: Multiple Myeloma Drugs Market: Breakup by End-User (in %), 2022
Figure 6: Global: Multiple Myeloma Drugs Market: Breakup by Distribution Channel (in %), 2022
Figure 7: Global: Multiple Myeloma Drugs Market: Breakup by Region (in %), 2022
Figure 8: Global: Multiple Myeloma Drugs Market Forecast: Sales Value (in Billion US$), 2023-2028
Figure 9: Global: Multiple Myeloma Drugs (Targeted Therapy) Market: Sales Value (in Million US$), 2017 & 2022
Figure 10: Global: Multiple Myeloma Drugs (Targeted Therapy) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 11: Global: Multiple Myeloma Drugs (Biologic Therapy) Market: Sales Value (in Million US$), 2017 & 2022
Figure 12: Global: Multiple Myeloma Drugs (Biologic Therapy) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 13: Global: Multiple Myeloma Drugs (Chemotherapy) Market: Sales Value (in Million US$), 2017 & 2022
Figure 14: Global: Multiple Myeloma Drugs (Chemotherapy) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 15: Global: Multiple Myeloma Drugs (Others) Market: Sales Value (in Million US$), 2017 & 2022
Figure 16: Global: Multiple Myeloma Drugs (Others) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 17: Global: Multiple Myeloma Drugs (Immunomodulatory Drugs) Market: Sales Value (in Million US$), 2017 & 2022
Figure 18: Global: Multiple Myeloma Drugs (Immunomodulatory Drugs) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 19: Global: Multiple Myeloma Drugs (Proteasome Inhibitors) Market: Sales Value (in Million US$), 2017 & 2022
Figure 20: Global: Multiple Myeloma Drugs (Proteasome Inhibitors) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 21: Global: Multiple Myeloma Drugs (Histone Deacetylase Inhibitors) Market: Sales Value (in Million US$), 2017 & 2022
Figure 22: Global: Multiple Myeloma Drugs (Histone Deacetylase Inhibitors) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 23: Global: Multiple Myeloma Drugs (Monoclonal Antibody Drugs) Market: Sales Value (in Million US$), 2017 & 2022
Figure 24: Global: Multiple Myeloma Drugs (Monoclonal Antibody Drugs) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 25: Global: Multiple Myeloma Drugs (Steroids) Market: Sales Value (in Million US$), 2017 & 2022
Figure 26: Global: Multiple Myeloma Drugs (Steroids) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 27: Global: Multiple Myeloma Drugs (Others) Market: Sales Value (in Million US$), 2017 & 2022
Figure 28: Global: Multiple Myeloma Drugs (Others) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 29: Global: Multiple Myeloma Drugs (Men) Market: Sales Value (in Million US$), 2017 & 2022
Figure 30: Global: Multiple Myeloma Drugs (Men) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 31: Global: Multiple Myeloma Drugs (Women) Market: Sales Value (in Million US$), 2017 & 2022
Figure 32: Global: Multiple Myeloma Drugs (Women) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 33: Global: Multiple Myeloma Drugs (Hospital Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
Figure 34: Global: Multiple Myeloma Drugs (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 35: Global: Multiple Myeloma Drugs (Retail Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
Figure 36: Global: Multiple Myeloma Drugs (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 37: Global: Multiple Myeloma Drugs (Online Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
Figure 38: Global: Multiple Myeloma Drugs (Online Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 39: Global: Multiple Myeloma Drugs (Others) Market: Sales Value (in Million US$), 2017 & 2022
Figure 40: Global: Multiple Myeloma Drugs (Others) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 41: North America: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 42: North America: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 43: United States: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 44: United States: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 45: Canada: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 46: Canada: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 47: Asia Pacific: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 48: Asia Pacific: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 49: China: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 50: China: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 51: Japan: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 52: Japan: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 53: India: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 54: India: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 55: South Korea: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 56: South Korea: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 57: Australia: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 58: Australia: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 59: Indonesia: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 60: Indonesia: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 61: Others: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 62: Others: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 63: Europe: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 64: Europe: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 65: Germany: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 66: Germany: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 67: France: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 68: France: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 69: United Kingdom: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 70: United Kingdom: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 71: Italy: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 72: Italy: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 73: Spain: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 74: Spain: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 75: Russia: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 76: Russia: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 77: Others: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 78: Others: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 79: Latin America: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 80: Latin America: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 81: Brazil: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 82: Brazil: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 83: Mexico: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 84: Mexico: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 85: Others: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 86: Others: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 87: Middle East and Africa: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 88: Middle East and Africa: Multiple Myeloma Drugs Market: Breakup by Country (in %), 2022
Figure 89: Middle East and Africa: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 90: Global: Multiple Myeloma Drugs Industry: SWOT Analysis
Figure 91: Global: Multiple Myeloma Drugs Industry: Value Chain Analysis
Figure 92: Global: Multiple Myeloma Drugs Industry: Porter’s Five Forces Analysis
Figure 1: Global: Multiple Myeloma Drugs Market: Major Drivers and Challenges
Figure 2: Global: Multiple Myeloma Drugs Market: Sales Value (in Billion US$), 2017-2022
Figure 3: Global: Multiple Myeloma Drugs Market: Breakup by Therapy (in %), 2022
Figure 4: Global: Multiple Myeloma Drugs Market: Breakup by Drug Type (in %), 2022
Figure 5: Global: Multiple Myeloma Drugs Market: Breakup by End-User (in %), 2022
Figure 6: Global: Multiple Myeloma Drugs Market: Breakup by Distribution Channel (in %), 2022
Figure 7: Global: Multiple Myeloma Drugs Market: Breakup by Region (in %), 2022
Figure 8: Global: Multiple Myeloma Drugs Market Forecast: Sales Value (in Billion US$), 2023-2028
Figure 9: Global: Multiple Myeloma Drugs (Targeted Therapy) Market: Sales Value (in Million US$), 2017 & 2022
Figure 10: Global: Multiple Myeloma Drugs (Targeted Therapy) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 11: Global: Multiple Myeloma Drugs (Biologic Therapy) Market: Sales Value (in Million US$), 2017 & 2022
Figure 12: Global: Multiple Myeloma Drugs (Biologic Therapy) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 13: Global: Multiple Myeloma Drugs (Chemotherapy) Market: Sales Value (in Million US$), 2017 & 2022
Figure 14: Global: Multiple Myeloma Drugs (Chemotherapy) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 15: Global: Multiple Myeloma Drugs (Others) Market: Sales Value (in Million US$), 2017 & 2022
Figure 16: Global: Multiple Myeloma Drugs (Others) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 17: Global: Multiple Myeloma Drugs (Immunomodulatory Drugs) Market: Sales Value (in Million US$), 2017 & 2022
Figure 18: Global: Multiple Myeloma Drugs (Immunomodulatory Drugs) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 19: Global: Multiple Myeloma Drugs (Proteasome Inhibitors) Market: Sales Value (in Million US$), 2017 & 2022
Figure 20: Global: Multiple Myeloma Drugs (Proteasome Inhibitors) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 21: Global: Multiple Myeloma Drugs (Histone Deacetylase Inhibitors) Market: Sales Value (in Million US$), 2017 & 2022
Figure 22: Global: Multiple Myeloma Drugs (Histone Deacetylase Inhibitors) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 23: Global: Multiple Myeloma Drugs (Monoclonal Antibody Drugs) Market: Sales Value (in Million US$), 2017 & 2022
Figure 24: Global: Multiple Myeloma Drugs (Monoclonal Antibody Drugs) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 25: Global: Multiple Myeloma Drugs (Steroids) Market: Sales Value (in Million US$), 2017 & 2022
Figure 26: Global: Multiple Myeloma Drugs (Steroids) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 27: Global: Multiple Myeloma Drugs (Others) Market: Sales Value (in Million US$), 2017 & 2022
Figure 28: Global: Multiple Myeloma Drugs (Others) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 29: Global: Multiple Myeloma Drugs (Men) Market: Sales Value (in Million US$), 2017 & 2022
Figure 30: Global: Multiple Myeloma Drugs (Men) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 31: Global: Multiple Myeloma Drugs (Women) Market: Sales Value (in Million US$), 2017 & 2022
Figure 32: Global: Multiple Myeloma Drugs (Women) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 33: Global: Multiple Myeloma Drugs (Hospital Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
Figure 34: Global: Multiple Myeloma Drugs (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 35: Global: Multiple Myeloma Drugs (Retail Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
Figure 36: Global: Multiple Myeloma Drugs (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 37: Global: Multiple Myeloma Drugs (Online Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
Figure 38: Global: Multiple Myeloma Drugs (Online Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 39: Global: Multiple Myeloma Drugs (Others) Market: Sales Value (in Million US$), 2017 & 2022
Figure 40: Global: Multiple Myeloma Drugs (Others) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 41: North America: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 42: North America: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 43: United States: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 44: United States: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 45: Canada: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 46: Canada: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 47: Asia Pacific: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 48: Asia Pacific: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 49: China: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 50: China: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 51: Japan: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 52: Japan: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 53: India: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 54: India: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 55: South Korea: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 56: South Korea: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 57: Australia: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 58: Australia: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 59: Indonesia: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 60: Indonesia: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 61: Others: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 62: Others: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 63: Europe: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 64: Europe: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 65: Germany: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 66: Germany: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 67: France: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 68: France: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 69: United Kingdom: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 70: United Kingdom: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 71: Italy: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 72: Italy: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 73: Spain: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 74: Spain: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 75: Russia: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 76: Russia: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 77: Others: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 78: Others: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 79: Latin America: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 80: Latin America: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 81: Brazil: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 82: Brazil: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 83: Mexico: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 84: Mexico: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 85: Others: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 86: Others: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 87: Middle East and Africa: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2017 & 2022
Figure 88: Middle East and Africa: Multiple Myeloma Drugs Market: Breakup by Country (in %), 2022
Figure 89: Middle East and Africa: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 90: Global: Multiple Myeloma Drugs Industry: SWOT Analysis
Figure 91: Global: Multiple Myeloma Drugs Industry: Value Chain Analysis
Figure 92: Global: Multiple Myeloma Drugs Industry: Porter’s Five Forces Analysis
